Dosing & Uses
Dosage Forms & Strengths
solution
- 43.5mg/mL (0.5%)
Onychomycosis of the Toenail
Indicated for onychomycosis of the toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes
Clean and dry nails prior to use; apply to completely cover nail surface and under tip of each nail being treated; allow solution to dry following application
Apply to affected toenails qDay for 48 weeks
Dosage Forms & Strengths
solution
- 43.5mg/mL (0.5%)
Onychomycosis of the Toenail
<6 years
- Safety and efficacy not established
≥6 years
- Indicated for onychomycosis of toenail(s) due to Trichophyton rubrum or Trichophyton mentagrophytes
- Clean and dry nails prior to use; apply to completely cover nail surface and under tip of each nail being treated; allow solution to dry following application
- Apply to affected toenails qDay for 48 weeks
Adverse Effects
1-10%
Application site exfoliation (2.7%)
Ingrown toenail (2.5%)
Application site erythema (1.6%)
Application site dermatitis (1.3%)
Postmarketing Reports
Hypersensitivity, contact allergy
Warnings
Contraindications
None reported by manufacturer
Cautions
Not for oral, ophthalmic, or intravaginal use
Avoid contact with eyes, mouth, vagina, or skin immediately surrounding treated nail; wipe away excess solution from surrounding skin
Product is flammable; avoid use near heat or open flame
Pregnancy & Lactation
Pregnancy
There are no available data on use in pregnant women to inform a drug associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes; in oral animal reproductive studies, administration of tavaborole during the period of organogenesis resulted in embryofetal toxicity and malformations at 570 times the Maximum Recommended Human Dose (MRHD) based on Area Under the Curve (AUC) comparisons in rats and embryofetal toxicity at 155 times the MRHD based on AUC comparisons in rabbits; embryofetal toxicity was noted following dermal administration in rabbits up to 36 times the MRHD based on AUC comparisons
Lactation
There is no information available on presence in human milk, effects on breastfed infant or on milk production in women who are breastfeeding; drug is systemically absorbed; lack of clinical data during lactation precludes a clear determination of risk of therapy to a breastfed infant; therefore, the developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from treatment or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
An oxaborole antifungal (boron-containing compound); inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS)
Elimination
Excretion: Urine (primarily)
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Kerydin topical - | 5 % solution | ![]() | |
Kerydin topical - | 5 % solution | ![]() |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.